March 9, 2026 Fixing the Validation Gap in Contract Manufacturing

As contract manufacturing grows, validation ownership becomes fragmented. Digital platforms can help restore oversight and traceability.

By Samy Siva, founder, CEO, and chief product strategist, ValGenesis, Inc.

Contract manufacturing has become a structural pillar of the life sciences industry. From pharmaceuticals and biologics to medical devices and diagnostics, companies are increasingly outsourcing production to contract development and manufacturing organizations (CDMOs) to scale faster, manage costs and access specialized capabilities.

But as reliance on external manufacturing partners grows, so does the validation gap.

Validation has always been central to regulatory compliance and patient safety. Yet in multiparty manufacturing environments, ownership of validation activities is no longer as clear-cut as it once was. Responsibilities are distributed across sponsors, contract manufacturers, and sometimes even third-party technology providers.

Validation Ownership Is Blurring

In traditional in-house manufacturing models, validation followed a relatively linear structure. The same organization designs the process, qualifies the equipment, validates the systems and maintains the documentation. Roles were clear, and accountability was centralized.

Contract manufacturing changes that equation.

Today, one organization may design a process, another may execute it, and a third may manage data or quality systems. Validation activities are often split across organizations with different systems, priorities and interpretations of regulatory expectations. While quality agreements are intended to define responsibilities, they frequently lack operational clarity. Many specify what must be validated but not how, when, or with what level of visibility. This creates ambiguity that may not surface until an audit, inspection or deviation investigation exposes it.

Regulators Are Increasingly Focused on Oversight Gaps

Regulatory agencies have made it clear that outsourcing manufacturing does not outsource accountability. The FDA, EMA and other global regulators consistently emphasize that product sponsors remain responsible for ensuring validated processes even when those processes are executed externally.

FDA warning letters over the past several years reflect a recurring theme: insufficient oversight of contract manufacturers, inadequate validation documentation and lack of control over computerized systems used in regulated production are the responsibility of the manufacturer. In many cases, findings do not stem from willful noncompliance, but from fragmented validation records, inconsistent data integrity controls, or unclear change management across organizational boundaries.

Regulators are no longer satisfied with static validation reports stored in silos. They expect continuous control, traceability and the ability to demonstrate that validated states are maintained throughout the product lifecycle even when multiple parties are involved.

Where Validation Gaps Typically Emerge

In contract manufacturing environments, validation gaps tend to surface in several predictable areas.

Why Traditional Approaches Are No Longer Enough

Historically, validation has relied heavily on document-centric approaches, including static protocols, manual approvals and episodic audits. While this model worked in simpler manufacturing environments, it struggles to scale in today’s distributed ecosystems.

Manual validation processes are slow, difficult to update and poorly suited for collaboration across organizations. They also make it challenging to demonstrate real-time compliance, which is increasingly expected by regulators.

Digital Validation as a Shared Control Layer

Digital validation platforms are emerging as a practical way to close the validation gap in contract manufacturing relationships without fundamentally changing regulatory expectations.

At their core, these platforms provide a shared system of record for validation activities. Instead of exchanging PDFs and spreadsheets, sponsors and contract manufacturers can collaborate within a common framework that tracks validation status, approvals, changes and evidence in real time.

This shared visibility enables clearer accountability. Each party can see who owns which validation tasks, how they are progressing and where dependencies exist. When changes occur, their impact on validated states can be assessed immediately rather than retroactively.

Importantly, digital validation platforms support lifecycle management. Validation is no longer treated as a static milestone but as an ongoing process that adapts as manufacturing conditions evolve.

Supporting Compliance Without Adding Friction

One of the most common concerns about digital validation is the fear of added complexity. In reality, the opposite is often true.

By standardizing workflows, automating documentation and integrating validation with quality and change management systems, digital platforms reduce manual effort and errors. They also make audits more efficient by providing regulators with structured, traceable evidence rather than fragmented records.

For contract manufacturing relationships, this approach fosters trust. Transparency replaces assumption, and collaboration replaces after-the-fact reconciliation.

Preparing for the Next Regulatory Expectation

The validation gap in contract manufacturing is already present. It shows up in disconnected documentation, unclear ownership, and delayed responses when questions are asked ― whether by quality teams or regulators. As organizations continue to expand their reliance on external partners, these gaps will only become more visible, and more difficult to explain after the fact.

Addressing this reality does not require new regulations or more complex quality frameworks. It requires a different operating mindset that treats validation as a shared, living responsibility rather than a series of static deliverables exchanged between organizations. Visibility, accountability and continuity must extend beyond organizational boundaries and persist long after initial qualification is complete.

Digital validation plays a critical role in making this possible — not by adding another layer of oversight, but by replacing assumption with evidence and alignment with traceability. Because when questions arise, the strength of a validation program is no longer measured by the volume of documents produced, but by the clarity of the answers it can provide.

About the Author:
Before founding ValGenesis, Siva Samy held technical and management positions at biotech, pharmaceutical, and medical device companies in validation and information technology. He has authored more than 15 research articles and holds a patent titled “Validating and Maintaining Respective Validation Status of Software Applications, Manufacturing Systems and Business Processes,” issued by the U.S. Patent and Trademark Office. He earned a master’s degree in analytical chemistry, a Ph.D. in medical devices, and a post-doctoral degree from the University of Madras and the University of Toronto.

Subscribe to Industry Today